

Functional (Non Ulcer) Dyspepsia - Pipeline Review, H2 2020

<https://marketpublishers.com/r/FBFA36E1FD2EN.html>

Date: July 2020

Pages: 36

Price: US\$ 2,000.00 (Single User License)

ID: FBFA36E1FD2EN

Abstracts

Functional (Non Ulcer) Dyspepsia - Pipeline Review, H2 2020

SUMMARY

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Functional Dyspepsia - Pipeline Review, H2 2020, provides an overview of the Functional Dyspepsia (Gastrointestinal) pipeline landscape.

Non-ulcer dyspepsia is a term used to describe signs and symptoms of indigestion that have no obvious cause. Non-ulcer dyspepsia is also called functional dyspepsia or non-ulcer stomach pain. Signs and symptoms include burning sensation or discomfort in upper abdomen or lower chest, sometimes relieved by food or antacids, bloating, belching and nausea. The predisposing factors include consuming excessive amounts of caffeine or alcohol, smoking and taking certain medications, especially certain over-the-counter pain relievers, such as aspirin and ibuprofen (advil, motrin, others), which can cause stomach problems. Treatment includes medications to reduce acid production, antibiotics and low-dose antidepressants.

REPORT HIGHLIGHTS

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Functional Dyspepsia - Pipeline Review, H2 2020, provides comprehensive information on the therapeutics under development for Functional Dyspepsia (Gastrointestinal), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Functional Dyspepsia (Gastrointestinal) pipeline guide also reviews of key players involved in therapeutic development for Functional (Non Ulcer) Dyspepsia and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies/Universities/Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I and Preclinical stages are 2, 1, 1 and 1 respectively. Similarly, the Universities portfolio in Discovery stages comprises 1 molecules, respectively.

Functional Dyspepsia (Gastrointestinal) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

SCOPE

The pipeline guide provides a snapshot of the global therapeutic landscape of Functional Dyspepsia (Gastrointestinal).

The pipeline guide reviews pipeline therapeutics for Functional Dyspepsia (Gastrointestinal) by companies and universities/research institutes based on information derived from company and industry-specific sources.

The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.

The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.

The pipeline guide reviews key companies involved in Functional Dyspepsia (Gastrointestinal) therapeutics and enlists all their major and minor projects.

The pipeline guide evaluates Functional Dyspepsia (Gastrointestinal) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.

The pipeline guide encapsulates all the dormant and discontinued pipeline projects.

The pipeline guide reviews latest news related to pipeline therapeutics for Functional Dyspepsia (Gastrointestinal)

REASONS TO BUY

Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.

Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.

Find and recognize significant and varied types of therapeutics under development for Functional Dyspepsia (Gastrointestinal).

Classify potential new clients or partners in the target demographic.

Develop tactical initiatives by understanding the focus areas of leading companies.

Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.

Formulate corrective measures for pipeline projects by understanding Functional Dyspepsia (Gastrointestinal) pipeline depth and focus of Indication therapeutics.

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.

Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Contents

Introduction

Global Markets Direct Report Coverage

Functional (Non Ulcer) Dyspepsia - Overview

Functional (Non Ulcer) Dyspepsia - Therapeutics Development

Pipeline Overview

Pipeline by Companies

Pipeline by Universities/Institutes

Products under Development by Companies

Products under Development by Universities/Institutes

Functional (Non Ulcer) Dyspepsia - Therapeutics Assessment

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Functional (Non Ulcer) Dyspepsia - Companies Involved in Therapeutics Development

Daewoong Pharmaceutical Co Ltd

RaQualia Pharma Inc

Renexxion LLC

Zeria Pharmaceutical Co Ltd

Functional (Non Ulcer) Dyspepsia - Drug Profiles

5-BIOP - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

acotiamide hydrochloride - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Functional (Non Ulcer) Dyspepsia - Dormant Projects

Functional (Non Ulcer) Dyspepsia - Discontinued Products

Functional (Non Ulcer) Dyspepsia - Product Development Milestones

Featured News & Press Releases

Mar 25, 2013: Zeria Pharma Receives Approval For Acofide In Japan For Treating

Functional Dyspepsia

Feb 29, 2012: RaQualia Pharma Receives MHRA Approval To Initiate First-In-Human

Study For 5-HT4 Partial Agonist RQ-00000010

Appendix

[Methodology](#)

[Coverage](#)

[Secondary Research](#)

[Primary Research](#)

[Expert Panel Validation](#)

[Contact Us](#)

[Disclaimer](#)

List Of Tables

LIST OF TABLES

Number of Products under Development for Functional (Non Ulcer) Dyspepsia, H2 2020

Number of Products under Development by Companies, H2 2020

Number of Products under Development by Universities/Institutes, H2 2020

Products under Development by Companies, H2 2020

Products under Development by Universities/Institutes, H2 2020

Number of Products by Stage and Target, H2 2020

Number of Products by Stage and Mechanism of Action, H2 2020

Number of Products by Stage and Route of Administration, H2 2020

Number of Products by Stage and Molecule Type, H2 2020

Functional (Non Ulcer) Dyspepsia - Pipeline by Daewoong Pharmaceutical Co Ltd, H2 2020

Functional (Non Ulcer) Dyspepsia - Pipeline by RaQualia Pharma Inc, H2 2020

Functional (Non Ulcer) Dyspepsia - Pipeline by Renexxion LLC, H2 2020

Functional (Non Ulcer) Dyspepsia - Pipeline by Zeria Pharmaceutical Co Ltd, H2 2020

Functional (Non Ulcer) Dyspepsia - Dormant Projects, H2 2020

Functional (Non Ulcer) Dyspepsia - Discontinued Products, H2 2020

List Of Figures

LIST OF FIGURES

Number of Products under Development for Functional (Non Ulcer) Dyspepsia, H2 2020

Number of Products under Development by Companies, H2 2020

Number of Products by Targets, H2 2020

Number of Products by Stage and Targets, H2 2020

Number of Products by Mechanism of Actions, H2 2020

Number of Products by Stage and Mechanism of Actions, H2 2020

Number of Products by Stage and Routes of Administration, H2 2020

Number of Products by Stage and Molecule Types, H2 2020

COMPANIES MENTIONED

Daewoong Pharmaceutical Co Ltd

RaQualia Pharma Inc

Renexxion LLC

Zeria Pharmaceutical Co Ltd

I would like to order

Product name: Functional (Non Ulcer) Dyspepsia - Pipeline Review, H2 2020

Product link: <https://marketpublishers.com/r/FBFA36E1FD2EN.html>

Price: US\$ 2,000.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/FBFA36E1FD2EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970